News World EU drug regulators step up work to prepare for 'no deal' Brexit

EU drug regulators step up work to prepare for ‘no deal’ Brexit

Drug regulators across Europe are hiring extra staff and increasing their workload as the role of British experts in the EU-wide system of medicines supervision winds down ahead of Brexit.

Although the UK’s exit from the European Union is still eight months away, Britain has already stopped taking on new projects that will extend beyond March 29, 2019 and is preparing to hand over existing drug review work to other countries.

That leaves a major gap, since British experts carry out around a fifth of the work for the centralised European Medicines Agency (EMA), the EU’s equivalent of the U.S. Food and Drug Administration.

In addition, Britain’s Medicines and Healthcare products Regulatory Agency also plays a pivotal role in Europe’s decentralised system of drug supervision, which is based on mutual recognition.

“It’s a real pity that we are going to lose the UK expertise, which is certainly very strong,” said Hugo Hurts, executive director of the Netherlands Medicines Evaluation Board.

“It’s a real challenge, but I’m not going to say there is not enough knowledge to replace that in the rest of the network,” Hurts told Reuters.

Germany, Sweden and the Netherlands are among the other big contributors to the EU drug review process, alongside Britain.

The Dutch agency has already added more than a dozen extra staff, and drug regulators in other EU states are also hiring more people.

In addition, officials are exploring how more drug assessment work can be performed by multinational teams in future, rather than just one agency.

Despite a vote by UK lawmakers this week calling for Britain’s continued participation in the Europe regulatory network for medicines, there is no certainty that any such deal will be reached.

That reflects the wider lack of clarity over Britain’s future relationship with the world’s biggest trading bloc after it leaves the EU next March.

“At the end of the day, the network has to be prepared for the worst-case scenario. If we are not prepared by March 29, 2019 for a ‘no deal’ Brexit then we would have done a very bad job,” Hurts said.

Maintaining timely approvals for new drugs is crucial for pharmaceutical and biotechnology companies, which have dozens of experimental medicines due to be assessed in the next couple of years.

The Brexit-induced disruption also comes at a time when regulators are having to grapple with oversight of a range of new health technologies, such as gene therapy, and a slew of big data on health outcomes.

Global drug companies, including UK-based GlaxoSmithKline and AstraZeneca, have been vocal in calling for continued close EU-UK ties after Brexit. The issue is also important to many Japanese drugmakers that have made Britain their European base.

The EMA itself is being uprooted from London to Amsterdam, increasing the pressure on the system for overseeing drug safety. Although Amsterdam is more attractive than other locations that might have been chosen, the agency is still braced for significant staff departures.

A staff survey last year predicted 19 percent employee losses from the move to Amsterdam, and the EMA’s executive director Guido Rasi said this was based on optimistic assumptions.

Meanwhile, individual drug companies are taking steps to prepare their supply lines in the event of a disorderly or no-deal Brexit that could threaten the smooth flow of products across borders.

AstraZeneca said this week it was increasing stockpiles of those medicines in Britain and Europe that could be affected by around 20 percent.

Top Stories

Commissioner Kyriakidou calls for urgent action to relieve pressure on public hospitals

  Health Commissioner Stella Kyriakidou called for urgent immediate action to protect lives following the rise in the percentages of covid-19 new cases throughout Europe. 'We...

Five students and two teachers tested positive to COVID-10 in occupied areas

Five students and two teachers have tested positive to COVID-19 in the occupied areas. This was announced by “education minister” Nazim Cavusoglu who added that...

New website of the Foreign Ministry in operation as of 27 October

As of yesterday, the new website of the Foreign Ministry is accessible at www.mfa.gov.cy. The new page aims to upgrade and make the public’s communication...

Professor Kostrikkis: Masks are like safety helmets

“I share the people’s discomfort from the use of the protective masks everywhere,” Leondios Kostrikis, Professor of Biological Sciences at the University of Cyprus...

Parties want to deprive corrupted officials from benefits

  DISY, EDEK and the Greens are looking to deprive benefits that state officials receive if they are found guilty of corruption charges. The parties have...

Taste

Squash soup

Ingredients: 1 kg pumpkin, cut into small cubes, approximately 5 cups 2 medium (400g) sweet potatoes, cut into cubes, approximately 2 ½ cups 1 chopped leek, only...

Mezedes

No visit to Cyprus is complete without enjoying the traditional meal of many small dishes known as ‘meze’. This large feast, which has been a...

Prawns with fried cheese, barley shaped pasta

Put the barley shaped pasta into a small pan with salted water, bring to a boil and when tender, drain. Peal the prawns leaving...

Salmon and shrimp sheftalies

Mix all ingredients for tabbouli in a bowl and keep to one side so flavours can combine. Prepare the sheftalies: wash and soak the casing...